Unicycive Therapeutics, Inc.
UNCYFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Unicycive Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Unicycive Therapeutics, Inc. — 10-K filed Mar 31, 2025
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 15, 2026. The latest institutional report shown is dated Mar 31, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 2025-03-31 | 0 | $0 | SEC filing |
| Vivo Capital, LLC | 2025-03-31 | 11,370,152 | Not shown | SEC filing |
| TANDEM CAPITAL MANAGEMENT CORP /ADV | 2025-03-31 | 15,500 | Not shown | SEC filing |
| Logos Global Management LP | 2025-03-31 | 5,078,927 | Not shown | SEC filing |
| Octagon Capital Advisors LP | 2025-03-31 | 10,000,000 | Not shown | SEC filing |
| Virtu Financial LLC | 2025-03-31 | 38,868 | Not shown | SEC filing |
| GREAT POINT PARTNERS LLC | 2025-03-31 | 10,980,000 | Not shown | SEC filing |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2025-03-31 | 2,413,489 | Not shown | SEC filing |
| Walleye Capital LLC | 2025-03-31 | 4,094,256 | Not shown | SEC filing |
| ACUTA CAPITAL PARTNERS, LLC | 2025-03-31 | 2,352,887 | Not shown | SEC filing |
| Hudson Bay Capital Management LP | 2025-03-31 | 14,840 | Not shown | SEC filing |
| STATE STREET CORP | 2025-03-31 | 125,236 | Not shown | SEC filing |
| Bogart Wealth, LLC | 2025-03-31 | 60 | Not shown | SEC filing |
| Alyeska Investment Group, L.P. | 2025-03-31 | 1,750,000 | Not shown | SEC filing |
| GOLDMAN SACHS GROUP INC | 2025-03-31 | 73,475 | Not shown | SEC filing |
| UBS Group AG | 2025-03-31 | 9,552 | Not shown | SEC filing |
| Creative Planning | 2025-03-31 | 25,910 | Not shown | SEC filing |
| SBI Securities Co., Ltd. | 2025-03-31 | 25 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-03-31 | 22,266 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-03-31 | 1,212,441 | Not shown | SEC filing |
- Each value is checked against Unicycive Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 19 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- NORTHERN TRUST CORP: 58,181 shares reported 2024-12-31; 107,850 shares reported 2025-03-31.
- BlackRock, Inc.: 72,272 shares reported 2024-12-31; 83,242 shares reported 2025-03-31.
- BANK OF AMERICA CORP /DE/: 406 shares reported 2024-12-31; 428 shares reported 2025-03-31.
- XTX Topco Ltd: 171,463 shares reported 2024-12-31; 123,233 shares reported 2025-03-31.
- Nantahala Capital Management, LLC: 10,391,994 shares reported 2024-12-31; 9,391,994 shares reported 2025-03-31.
- JPMORGAN CHASE & CO: 199 shares reported 2024-12-31; 184 shares reported 2025-03-31.
- HRT FINANCIAL LP: 22,131 shares reported 2024-12-31; 17,816 shares reported 2025-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 524,487 shares reported 2024-12-31; 579,202 shares reported 2025-03-31.
- TWO SIGMA SECURITIES, LLC: 23,266 shares reported 2024-09-30; 12,044 shares reported 2025-03-31.
- VANGUARD GROUP INC: 1,138,220 shares reported 2024-12-31; 1,212,441 shares reported 2025-03-31.
- SBI Securities Co., Ltd.: 49 shares reported 2024-12-31; 25 shares reported 2025-03-31.
- Creative Planning: 22,674 shares reported 2024-12-31; 25,910 shares reported 2025-03-31.
Showing the 12 most recent filer reports.
16 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2022-05-16 | Schiller Brigitte · Director | Common Stock | P — Open market or private purchase | +15,000 | 0.83 | SEC filing |
Showing 1 of 1 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-14 (amended) | Kenkare-Mitra Sara · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +42,100 | SEC filing |
| 2026-05-14 (amended) | Kenkare-Mitra Sara · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +84,200 | SEC filing |
| 2026-05-14 (amended) | Jermasek Douglas · EVP, Corporate Strategy | Restricted Stock Units | A — Grant, award, or other acquisition | +169,500 | SEC filing |
| 2026-05-14 (amended) | Laumas Sandeep · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +84,200 | SEC filing |
| 2026-05-14 (amended) | Laumas Sandeep · Director | Restricted Stock Units | A — Grant, award, or other acquisition | +42,100 | SEC filing |
| 2026-05-14 (amended) | Townsend John · CFO | Restricted Stock Unit | A — Grant, award, or other acquisition | +169,500 | SEC filing |
| 2026-05-14 (amended) | Gupta Shalabh K. · CEO | Restricted Stock Units | A — Grant, award, or other acquisition | +762,200 | SEC filing |
| 2026-05-14 (amended) | Gupta Pramod · EVP, Pharmaceuticals and BD | Restricted Stock Unit | A — Grant, award, or other acquisition | +169,500 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-08-25 | Aggarwal Gaurav · Director | Series A-2 Prime Preferred Stock | D — Disposition to the issuer | −3,199 | SEC filing |
| 2025-02-18 | Aggarwal Gaurav · Director | Series A-2 Prime Preferred Stock | D — Disposition to the issuer | −686 | SEC filing |
| 2024-10-09 | Aggarwal Gaurav · Director | Series A-2 Prime Preferred Stock | D — Disposition to the issuer | −2,695 | SEC filing |
Showing 3 of 3 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.